Prothena Corporation plc is a late-stage clinical biotech company focused on novel therapies for protein dysregulation diseases. Its developing birtamimab for AL amyloidosis, Prasinezumab for Parkinsons disease and related synucleinopathies, NNC6019 for ATTR amyloidosis, and BMS-986446/PRX012 for Alzheimers disease. The company also has preclinical programs for PRX123 (Alzheimers) and PRX019/neurogenerative diseases/TDP-43 (amyotrophic lateral sclerosis). Prothena has partnerships with Roche and Bristol-Myers Squibb to develop and commercialize antibodies targeting a-synuclein, tau, and TDP-43.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 0.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 3.0 |